title: Secondary acute myeloid leukemia following treatment with VP16-containing regimens for non-Hodgkin's lymphoma.
abstract: We report on two patients who developed a secondary acute myeloid leukemia (sAL) after treatment for non-Hodgkin's lymphoma (NHL) with regimens containing low to intermediate doses of VP16. Clinical and hematologic features in these two patients were consistent with epipodophyllotoxin-associated sAL. In one case, a rearrangement of chromosome band 11q23 was detected.
authors.forename: E
authors.initials: E
authors.lastname: Orlandi
authors.forename: M
authors.initials: M
authors.lastname: Lazzarino
authors.forename: P
authors.initials: P
authors.lastname: Bernasconi
authors.forename: C
authors.initials: C
authors.lastname: Astori
authors.forename: C
authors.initials: C
authors.lastname: Bernasconi
mesh_terms: D000328:Adult; D000368:Aged; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage / Q000009:adverse effects*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001761:Bleomycin / Q000008:administration & dosage; D003520:Cyclophosphamide / Q000008:administration & dosage; D003561:Cytarabine / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D004791:Enzyme Inhibitors / Q000008:administration & dosage / Q000009:adverse effects; D005047:Etoposide / Q000008:administration & dosage / Q000009:adverse effects*; D017809:Fatal Outcome; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage / Q000009:adverse effects; D006801:Humans; D007069:Ifosfamide / Q000008:administration & dosage; D007948:Leukemia, Monocytic, Acute / Q000139:chemically induced*; D015479:Leukemia, Myelomonocytic, Acute / Q000139:chemically induced*; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy*; D016399:Lymphoma, T-Cell / Q000188:drug therapy*; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage; D008942:Mitoxantrone / Q000008:administration & dosage; D009363:Neoplasm Proteins / Q000037:antagonists & inhibitors; D016609:Neoplasms, Second Primary / Q000139:chemically induced*; D011241:Prednisone / Q000008:administration & dosage; D059005:Topoisomerase II Inhibitors; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D004791:Enzyme Inhibitors; D009363:Neoplasm Proteins; D059005:Topoisomerase II Inhibitors; D003561:Cytarabine; D001761:Bleomycin; D016179:Granulocyte Colony-Stimulating Factor; D014750:Vincristine; D005047:Etoposide; D004317:Doxorubicin; D003520:Cyclophosphamide; D008942:Mitoxantrone; D007069:Ifosfamide; D011241:Prednisone; D008727:Methotrexate